Organon & Co. (7XP)
XDUS
Closed
Aug 24, 2026
Day's Range
11.6552 wk Range
4.97Overview - 7XP - Organon & Co.
Key Statistics
Valuation
Enterprise Value
8.07B
P/E (Trailing)
‪16.31‬
PEG Ratio
‪-0.60‬
Price / Book
‪3.06‬
EV / EBITDA
‪4.73‬
Profitability
Gross Margin
‪54.36%‬
Profit Margin
‪53.29%‬
Operating Margin
‪14.94%‬
Return on Assets
‪1.45%‬
Return on Equity
‪24.86%‬
Ownership
Shares Outstanding
262.60M
Price stats
50-Day Avg
‪11.76‬
200-Day Avg
‪8.62‬
Dividends
Frequency
Quarterly
Peers - 7XP - Organon & Co.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on XDUS.
- 7XPXDUSOrganon & Co.+31.76%52-week change16.18P/E (Trailing)‪53.29%‬Profit Margin
- LLYXDUSEli Lilly and Company+44.43%52-week change46.77P/E (Trailing)‪83.04%‬Profit Margin
- BAYAXDUSBayer AG Sponsored ADR+42.31%52-week change-12.72P/E (Trailing)‪58.75%‬Profit Margin
- 6MKXDUSMerck & Co., Inc.+41.66%52-week change17.34P/E (Trailing)‪74.80%‬Profit Margin
- IDPXDUSBiogen Inc.+36.31%52-week change20.87P/E (Trailing)‪75.69%‬Profit Margin
- JNJXDUSJohnson & Johnson+33.91%52-week change20.83P/E (Trailing)‪67.87%‬Profit Margin
- JNJ0XDUSJohnson & Johnson CDR+32.38%52-week change19.41P/E (Trailing)‪67.87%‬Profit Margin
Profile Summary - 7XP - Organon & Co.
About
Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies. Its primary focus areas include women’s health, biosimilars, and established brands, addressing key therapeutic needs in reproductive health, dermatology,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
